Trials / Completed
CompletedNCT04569695
A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants
A Phase 1, Randomized, Open-label, Parallel-group, Single- and Multiple-dose Study to Characterize Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to characterize the pharmacokinetics of single and multiple doses of JNJ-70033093 (BMS-986177) in healthy Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-70033093 | JNJ-70033093 capsule will be administered orally as per assigned treatment regimen. |
Timeline
- Start date
- 2021-03-08
- Primary completion
- 2021-12-04
- Completion
- 2021-12-16
- First posted
- 2020-09-30
- Last updated
- 2025-03-30
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04569695. Inclusion in this directory is not an endorsement.